Skip to main content

Table 2 Crude incidence rates for acute coronary syndrome in study cohorts a

From: The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

  TNFi-exposed RA patients (N = 7,704)   Biologic-naïve RA patients (N = 23,112)   General population referents (N = 38,520)  
Risk window b ACS/person-years Crude IR ACS/person-years Crude IR ACS/person-years Crude IR
Ever exposed to TNFi 221/32,621 6.8 (5.9 to 7.7) 680/75,268 9.0 (8.4 to 9.7) 602/165,603 3.6 (3.4 to 3.9)
Actively on TNFi 137/24,055 5.7 (4.8 to 6.7) 476/55,654 8.6 (7.8 to 9.4) 394/118,801 3.3 (3.0 to 3.7)
Short-term exposure 74/11,671 6.3 (5.0 to 8.0) 316/35,204 9.0 (8.0 to 10.0) 216/66,404 3.3 (2.8 to 3.7)
  1. aACS, Acute coronary syndrome; IR, Incidence ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. ‘Crude IR’ is the incidence per 1,000 person-years expressed as incidence rate (95% confidence interval). b‘Ever exposed’ is all follow-up time after exposure was evaluated, ‘Actively on TNFi’ includes follow-up time until reported stop date for the TNFi plus 90 days and corresponding date for referents and ‘Short-term exposure’ is defined as actively on TNFi with follow-up limited to 2 years.